Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Nov 28, 2025 | (Q4)Nov 28, 2025 | (Q3)Aug 29, 2025 | (Q2)May 30, 2025 | (Q1)Feb 28, 2025 | (FY)Nov 29, 2024 | (Q4)Nov 29, 2024 | (Q3)Aug 30, 2024 | (Q2)May 31, 2024 | (Q1)Mar 1, 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 24.52%10.03B | 8.18%3.16B | 8.76%2.2B | 12.94%2.19B | 111.41%2.48B | 10.33%8.06B | 82.91%2.92B | 7.90%2.02B | -9.30%1.94B | 1.17B |
| Net income from continuing operations | 28.24%7.13B | 10.28%1.86B | 5.23%1.77B | 7.50%1.69B | 192.10%1.81B | 2.43%5.56B | 13.49%1.68B | 20.03%1.68B | 21.47%1.57B | --620M |
| Operating gains losses | ---- | ---- | ---- | ---- | ---- | 6.94%77M | 16.67%21M | 5.56%19M | ---- | ---- |
| Depreciation and amortization | -4.55%818M | -15.60%184M | -2.35%208M | -2.34%209M | 2.36%217M | -1.72%857M | -1.80%218M | -2.29%213M | -2.73%214M | --212M |
| Asset impairment expenditure | ---- | --0 | ---- | ---- | ---- | --78M | ---- | ---- | ---- | ---- |
| Unrealized gains and losses of investment securities | ---- | ---- | ---- | ---- | ---- | -250.00%-35M | -266.67%-11M | -100.00%-10M | ---- | ---- |
| Remuneration paid in stock | 5.95%1.94B | 10.88%489M | 4.85%497M | 3.00%481M | 5.32%475M | 6.69%1.83B | 3.28%441M | 7.24%474M | 7.85%467M | --451M |
| Deferred tax | ---- | ---- | 0.00%-103M | 2.46%-119M | -45.69%-169M | -9.86%-468M | 15.33%-127M | 4.63%-103M | -2.52%-122M | ---116M |
| Other non cashItems | -820.00%-72M | -251.61%-109M | -83.33%2M | -21.74%18M | 183.33%17M | 233.33%10M | ---31M | --12M | 1,050.00%23M | --6M |
| Change In working capital | 319.44%604M | 19.94%740M | 31.27%-178M | 58.60%-89M | 13,000.00%131M | 140.56%144M | 253.10%617M | -164.29%-259M | -172.15%-215M | --1M |
| -Change in receivables | ---- | ---- | -88.95%-359M | -45.89%237M | -41.57%97M | 189.94%143M | 27.93%-271M | -13.10%-190M | 277.59%438M | --166M |
| -Change in prepaid assets | ---- | ---- | 140.51%64M | 86.11%-65M | 9.83%-156M | 24.69%-616M | 690.32%183M | 29.78%-158M | -53.95%-468M | ---173M |
| -Change in payables and accrued expense | ---- | ---- | 36.64%-83M | -143.93%-105M | 73.03%-41M | 258.14%308M | 176.03%352M | -167.88%-131M | -58.93%239M | ---152M |
| -Change in other working capital | 228.48%1.02B | 109.63%740M | -9.09%200M | 63.21%-156M | 44.38%231M | -42.35%309M | -24.41%353M | 115.69%220M | -341.67%-424M | --160M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 24.52%10.03B | 8.18%3.16B | 8.76%2.2B | 12.94%2.19B | 111.41%2.48B | 10.33%8.06B | 82.91%2.92B | 7.90%2.02B | -9.30%1.94B | --1.17B |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -896.64%-1.19B | -868.42%-146M | -493.62%-279M | -350.45%-278M | -833.33%-484M | -80.80%149M | -87.58%19M | -132.41%-47M | -65.53%111M | 66M |
| Net PPE purchase and sale | 2.19%-179M | 29.17%-34M | -26.32%-72M | -14.63%-47M | 29.73%-26M | 49.17%-183M | -2.13%-48M | 37.36%-57M | 66.12%-41M | ---37M |
| Net business purchase and sale | ---- | ---- | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Net investment purchase and sale | -398.49%-991M | -267.16%-112M | -2,000.00%-190M | -251.97%-231M | -544.66%-458M | -70.77%332M | -66.50%67M | -95.76%10M | -65.69%152M | --103M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -896.64%-1.19B | -868.42%-146M | -493.62%-279M | -350.45%-278M | -833.33%-484M | -80.80%149M | -87.58%19M | -132.41%-47M | -65.53%111M | --66M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -43.19%-11.06B | -2.16%-2.56B | 23.52%-1.88B | -490.03%-3.79B | -33.51%-2.84B | -49.05%-7.72B | -105.51%-2.5B | -181.63%-2.45B | 40.56%-642M | -2.13B |
| Net issuance payments of debt | ---- | ---- | --0 | --0 | --497M | 499.40%2B | --0 | --0 | --2B | --0 |
| Net common stock issuance | -19.63%-10.93B | 1.04%-2.47B | 19.28%-1.81B | -40.00%-3.5B | -65.74%-3.15B | -123.67%-9.14B | -150.00%-2.5B | -195.77%-2.24B | -150.25%-2.5B | ---1.9B |
| Net other financing activities | -7.22%-624M | -8,000.00%-81M | 67.28%-71M | -107.19%-288M | 18.22%-184M | 2.35%-582M | 99.54%-1M | -88.70%-217M | -71.60%-139M | ---225M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -43.19%-11.06B | -2.16%-2.56B | 23.52%-1.88B | -490.03%-3.79B | -33.51%-2.84B | -49.05%-7.72B | -105.51%-2.5B | -181.63%-2.45B | 40.56%-642M | ---2.13B |
| Net cash flow | ||||||||||
| Beginning cash position | 6.61%7.61B | -30.74%4.98B | -35.63%4.93B | 8.06%6.76B | 6.61%7.61B | 68.58%7.14B | 8.97%7.19B | 40.40%7.66B | 53.59%6.25B | --7.14B |
| Current changes in cash | -560.71%-2.22B | 4.56%459M | 108.98%43M | -233.07%-1.88B | 5.07%-843M | -83.39%481M | -17.64%439M | -141.76%-479M | 2.03%1.41B | ---888M |
| Effect of exchange rate changes | 477.78%34M | 47.37%-10M | -33.33%8M | 1,700.00%48M | -1,300.00%-12M | -200.00%-9M | -371.43%-19M | 700.00%12M | -200.00%-3M | --1M |
| End cash Position | -28.66%5.43B | -28.66%5.43B | -30.74%4.98B | -35.63%4.93B | 8.06%6.76B | 6.61%7.61B | 6.61%7.61B | 8.97%7.19B | 40.40%7.66B | --6.25B |
| Free cash from | 25.14%9.85B | 8.81%3.13B | 8.25%2.13B | 12.90%2.14B | 116.01%2.46B | 13.41%7.87B | 85.35%2.87B | 10.21%1.96B | -5.90%1.9B | --1.14B |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.